1. Home
  2. FAC vs AUTL Comparison

FAC vs AUTL Comparison

Compare FAC & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Factorial Energy Inc. Class A Common Stock

FAC

Factorial Energy Inc. Class A Common Stock

N/A

Current Price

$4.61

Market Cap

561.9M

Sector

Miscellaneous

ML Signal

N/A

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

N/A

Current Price

$2.41

Market Cap

532.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FAC
AUTL
Founded
N/A
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
561.9M
532.3M
IPO Year
2025
2025

Fundamental Metrics

Financial Performance
Metric
FAC
AUTL
Price
$4.61
$2.41
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
272.1K
3.2M
Earning Date
N/A
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,120,000.00
Revenue This Year
N/A
$80.32
Revenue Next Year
N/A
$53.96
P/E Ratio
N/A
N/A
Revenue Growth
N/A
496.00
52 Week Low
$4.24
$1.18
52 Week High
$15.40
$2.58

Technical Indicators

Market Signals
Indicator
FAC
AUTL
Relative Strength Index (RSI) 27.72 67.39
Support Level $4.27 $1.31
Resistance Level $6.32 $2.43
Average True Range (ATR) 0.45 0.19
MACD 0.09 0.04
Stochastic Oscillator 6.34 80.13

Price Performance

Historical Comparison
FAC
AUTL

About FAC Factorial Energy Inc. Class A Common Stock

Factorial Energy Inc is an American solid-state battery innovator backed by In-Q-Tel - the not-for-profit strategic investor for the U.S. national security community and America's allies - and Mercedes-Benz, Stellantis, Hyundai, and Kia. Through its proprietary FEST and Solstice platforms, engineered for scalable manufacturing, it delivers industry performance across defense, space, and energy storage applications. Mercedes-Benz's real-world road testing in a lightly modified test vehicle achieved over 1,200 km of range on a single charge, while Stellantis-lab testing verified 77 Ah cells demonstrating high energy density, fast-charging, and robust use for energy and power performance across temperature extremes.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Share on Social Networks: